Aurobindo Pharma

AUROPHARMA.NS

Hyderabad, India· Est. 1986

aurobindo.com

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

AUROPHARMA.NS · Stock Price

INR 1,478.70+314.30 (+26.99%)

Market Cap: $9.1B

Historical price data

Market Cap: $9.1BPipeline: 6 drugs (3 Phase 3)Patents: 20Founded: 1986Employees: 20,000+HQ: Hyderabad, India

Sector Ranking#15 in Small Molecule Drugs #9 in Biologics / Biosimilars

Overview

Founded in 1986, Aurobindo Pharma has grown from an API manufacturer into a global generics powerhouse with a mission to make medicines affordable and accessible worldwide. Its core strategy leverages deep vertical integration, significant manufacturing scale (29 facilities producing 50+ billion formulation units annually), and a strategic pivot towards high-value complex generics, injectables, and biosimilars. Key achievements include a portfolio of over 830 ANDA filings in the US with 600+ approvals, leadership in antiretroviral therapies, and the recent inauguration of a flagship Penicillin-G facility, underscoring its commitment to backward integration and supply chain resilience.

Broad GenericsInfectious Disease (HIV/AIDS, Anti-infectives)OncologyImmunologyCentral Nervous SystemCardiovascular

Technology Platform

Vertically integrated pharmaceutical manufacturing platform encompassing API synthesis & fermentation, complex generic formulation development (injectables, controlled-release), and a dedicated biosimilars & peptides development engine (Curateq).

Pipeline

6 drugs in pipeline3 in Phase 3

Drug	Indication	Stage
Test Product + Reference Product + Placebo	Bronchial Asthma	Phase 3
Adapalene 0.1% Gel + Differin 0.1% Topical Gel	Acne Vulgaris	Phase 3
Albuterol Sulfate HFA 0.09 mg (Reference) + Albuterol Sulfat...	Bronchial Asthma	Phase 3
Amphotericin B Liposome + AmBisome (Amphotericin B) Liposome	Visceral Leishmaniasis	Phase 1
Amlodipine - reference + Amlodipine ODT - test + Amlodipine ...	Healthy Volunteers	Phase 1

Funding History

IPOUndisclosedUndisclosedJun 15, 1995

FDA Approved Drugs

CITALOPRAM HYDROBROMIDEANDAMar 13, 2026

EVEROLIMUSANDAFeb 25, 2026

ARIPIPRAZOLEANDAFeb 18, 2026

Opportunities

The global shift towards complex generics and biosimilars presents a high-growth, higher-margin opportunity that aligns perfectly with Aurobindo's R&D investments.

Additionally, strategic backward integration into critical antibiotic APIs (Penicillin-G) positions the company to address global supply shortages and secure a stable, essential medicine franchise.

Risk Factors

Significant regulatory risk from stringent FDA and EMA inspections of its vast manufacturing network, and intense pricing pressure in the core US generics market which could erode margins.

The biosimilars pipeline also carries high development cost, litigation, and commercial execution risks.

Competitive Landscape

Aurobindo competes with large Indian peers (Sun Pharma, Dr. Reddy's) and global generics firms (Teva, Viatris). Its primary competitive advantages are deep vertical integration for cost control, scale (#1 in US prescriptions), and a strategic pivot towards complex products that face less commoditized competition.